Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Alector $125 million at-the-market offering
We advised the sales agent on the offering
Roche acquisition of PathAI
We are advising Roche on the transaction
Cross Country Healthcare sale to Knox Lane
We are advising Cross Country Healthcare on the transaction
CellCentric $220 million Series D financing round
We advised Venrock Healthcare Capital Partners
Oruka Therapeutics $700 million follow-on offering
We advised Oruka on the offering
GH Research $117.5 million follow-on offering
We advised GH Research on the offering
Avalyn Pharma $300 million IPO
We advised the underwriters on the IPO
Mabwell Bioscience HK$1.2 billion IPO
We advised Mabwell on its IPO and HKEX listing
Maze Therapeutics $150 million offering
We advised the sole underwriter on the offering
McKesson sale of minority stake in Medical-Surgical Solutions to Apollo
We are advising McKesson on the transaction